Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Feb 9, 2021 · 10-Q · 40 days after period end · 0001171843-21-000849
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Revenue | $81.00K | — |
| Net Income | -$3.22M | -$12.12M |
| EPS Diluted | -$0.26 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Feb 9, 2021 · 40 d after period end
